文献速递血脂与心血管预防

基线循环PCSK9水平与依洛尤单抗疗效的关联

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
PubMed 文献 · JAMA Cardiol · 2017-01-01

该研究汇总4项3期随机临床试验共3016例患者数据,按基线PCSK9水平四分位分组,评估依洛尤单抗140mg每2周或420mg每月一次降低LDL-C的百分比变化。结果显示无论基线PCSK9水平如何,两种剂量均一致且显著降低LDL-C达64%至71%(P<.001),交互作用P值分别为.76和.21。

要点

  • 基线PCSK9中位数为323 ng/mL(四分位距258-406 ng/mL)。
  • PCSK9较高四分位患者更常接受强化他汀治疗且基线LDL-C更低。
  • 依洛尤单抗两种剂量在各PCSK9四分位均降低LDL-C 64%至71%。

核心结论

  • 无论基线PCSK9水平如何,所研究的依洛尤单抗剂量均抑制PCSK9水平并一致且大幅降低LDL-C水平。

研究设计与样本

  • 汇总4项3期随机临床试验共3016例患者数据,按基线PCSK9四分位分层,另在4项2期试验的138例患者中每周测量PCSK9。

主要发现

  • 基线PCSK9中位数为323 ng/mL(四分位距258-406 ng/mL)。
  • PCSK9较高四分位患者更可能接受强化他汀治疗(第四至第一四分位分别为56%、36%、25%、13%,P < .001)。
  • PCSK9较高四分位患者基线LDL-C显著更低(第四至第一四分位分别为123 mg/dL、124 mg/dL、128 mg/dL、137 mg/dL,P < .001)。
  • 按他汀使用分层后,PCSK9与LDL-C无相关性(非他汀使用者ρ=0.03 [95% CI, -0.04至0.10],P=.39;他汀使用者ρ=0.03 [95% CI, -0.01至0.08],P=.12)。
  • 依洛尤单抗140 mg每2周和420 mg每月一次在各PCSK9四分位均使循环PCSK9在给药1周内抑制90%至100%,LDL-C降低64%至71%(P < .001),交互作用P值分别为.76和.21。

关键数值与推荐

  • 基线PCSK9中位数323 ng/mL(四分位距258-406 ng/mL)。
  • 依洛尤单抗140 mg每2周降低LDL-C 64%至71%(P < .001),交互作用P=.76。
  • 依洛尤单抗420 mg每月一次降低LDL-C 64%至71%(P < .001),交互作用P=.21。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Levels of proprotein convertase subtilisin kexin type 9 (PCSK9) vary markedly across the population and are influenced by genetic and nongenetic factors. Evolocumab is a fully human, monoclonal antibody against PCSK9 that reduces low-density lipoprotein cholesterol (LDL-C) levels by 55% to 75%. Whether the efficacy of evolocumab varies based on an individual's baseline PCSK9 level remains unknown. OBJECTIVE: To characterize variability in PCSK9 levels and determine whether the LDL-C level reduction achieved with evolocumab differs based on PCSK9 levels. DESIGN, SETTING, AND PARTICIPANTS: This study included pooled data from 3016 patients from 4 phase 3 randomized clinical trials of evolocumab as part of the Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 in Different Populations. Circulating PCSK9 levels were measured at baseline using quantitative enzyme-linked immunosorbent assays and used to stratify patients into quartiles, and LDL-C level was measured at baseline and weeks 10 and 12. In an additional 138 patients enrolled in a pharmacokinetic and pharmacodynamic substudy from 4 phase 2 trials, circulating PCSK9 levels were measured at baseline and then weekly at weeks 8 through 12. MAIN OUTCOMES AND MEASURES: Placebo-controlled percentage change in LDL-C level with evolocumab, 140 mg every 2 weeks and 420 mg once monthly, across quartiles of baseline PCSK9 levels. RESULTS: Of the 3016 patients, 1492 (49.5%) were female and 2758 (91.4%) were white. The median baseline circulating PCSK9 level was 323 ng/mL (interquartile range, 258-406 ng/mL). Patients with higher levels of PCSK9 were more likely to be receiving intensive statin therapy (56%, 36%, 25%, and 13% in the fourth through first quartiles; P < .001) and had significantly lower baseline LDL-C level (123 mg/dL, 124 mg/dL, 128 mg/dL, and 137 mg/dL in the fourth through first quartiles; P < .001). After stratifying by statin use, there was no correlation between PCSK9 levels and LDL-C levels (ρ = 0.03 [95% CI, -0.04 to 0.10] for nonstatin users, P = .39, and ρ = 0.03 [95% CI, -0.01 to 0.08] for statin users, P = .12). Across all quartiles of baseline PCSK9 levels, both evolocumab 140 mg every 2 weeks and 420 mg once monthly suppressed circulating PCSK9 levels by 90% to 100% within 1 week of administration. Both evolocumab 140 mg every 2 weeks and 420 mg once monthly were associated with significant reductions in LDL-C levels between 64% and 71% (P < .001), regardless of PCSK9 levels (P for interaction = .76 and .21, respectively). CONCLUSIONS AND RELEVANCE: Regardless of baseline PCSK9 levels, the doses of evolocumab being studied in a large cardiovascular outcomes trial suppress PCSK9 levels and consistently and substantially reduce LDL-C levels.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Desai NR, Giugliano RP, Wasserman SM, et al. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. JAMA Cardiol. 2017. PMID: 28122070. doi:10.1001/jamacardio.2016.5395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。